1. Impact of Chemotherapy Delay on Overall Survival for AML with I DH1/2 Mutations: A Study in Adult Chinese Patients
- Author
-
Wen Juan Yu, Ying Li, Meng Xia Yu, Hui Shi, Li Ping Mao, Xiu Feng Yin, Dongmei Wang, Fan Ping Wang, Sha Sha Lu, Hong Yan Tong, Jie Jin, Qiong Hong Xie, Ye Jiang Lou, Gai Xiang Xu, Qiu Ling Ma, Jing Han Wang, Min Yang, Dan Shen, li Ya Ma, Jian Huang, Yue Hong Jiang, Ju Ying Wei, Qi Guo, Jian Hu Li, and Zhi Xin Ma
- Subjects
Oncology ,medicine.medical_specialty ,NPM1 ,Chemotherapy ,IDH1 ,business.industry ,medicine.medical_treatment ,Immunology ,Myeloid leukemia ,Context (language use) ,Cell Biology ,Hematology ,Biochemistry ,Chemotherapy regimen ,Internal medicine ,CEBPA ,medicine ,Adverse effect ,business - Abstract
The effect of time from diagnosis to treatment (TDT) on overall survival of patients with acute myeloid leukemia (AML) remain obscure. Furthermore, whether chemotherapy delay impacts overall survival (OS) of patients with a special molecular subtype has not been investigated. Here, we enrolled 364 cases of AML to assess the effect of TDT on OS by fractional polynomial regression in the context of clinical parameters and genes of FLT3 ITD, NPM1, CEBPA, DNMT3a, and IDH1/2 mutations. Results of the current study show IDH1/2 mutations are associated with older age, M0 morphology, an intermediate cytogenetic risk group, and NPM1 mutations. TDT associates with OS for AML patients in a nonlinear pattern with a J shape. Moreover, adverse effect of delayed treatment on OS was observed in patients with IDH1/2 mutations, but not in those with IDH1/2 wild type. Therefore, initiating chemotherapy as soon as possible after diagnosis might be a potential strategy to improve OS in AML patients with IDH1/2 mutations. Disclosures No relevant conflicts of interest to declare.
- Published
- 2015